Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Vildagliptin & Type 2 Diabetes (T2D), the European Commission approved vildagliptin in 2007–2008 as a once-daily DPP-4 inhibitor for adults with type 2 diabetes (T2D) to enhance glycemic control. It can be used as monotherapy when metformin is unsuitable or in combination with other glucose-lowering agents, including insulin.
Galvus | European Medicines Agency (EMA)
see also:
[CD26 (Dipeptidyl peptidase 4) (DPP4) inhibitors & Type 2 Diabetes (T2D)](brain://…